<DOC>
	<DOCNO>NCT00539448</DOCNO>
	<brief_summary>Primary objective : To evaluate efficacy ( term change HbA1c reading start baseline 13 week &amp; end study 26 week ) subject type I diabetes mellitus . Secondary objective : - Recording average daily dose insulin Glulisine &amp; insulin Glargine type I DM . - Recording adverse event .</brief_summary>
	<brief_title>Gulf , Lantus , Apidra Evaluation Type 1 Diabetics Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Newly diagnose type I diabetic patient Type I diabetes treated basalbolus regimen include 3 injection Regular Human Insulin per day BMI , 2640 kg/m2 HbA1c , 7.5 % 10 % Median 2Hrs post prandial equal 140 mg/dl ( equal 7.8 mmol/L ) FPG equal 120 mg/dl ( equal 6.7 mmol/L ) Willingness accept , ability inject insulin Glargine therapy Pregnancy : The use LANTUS &amp; APIDRA pregnancy contraindicate . However , absence supportive data , Sanofi Aventis Pharmaceuticals specifically recommend use Lantus patient population The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>